Rethinking Alzheimer’s Disease Therapy: Are Mitochondria the Key?

Maria Ankarcrona\textsuperscript{a,\ast}, Francesca Mangialasche\textsuperscript{b,c} and Bengt Winblad\textsuperscript{a}

\textsuperscript{a}KI-Alzheimer’s Disease Research Center, Karolinska Institutet, Department of Neurobiology, Care Sciences and Society (NVS), Huddinge, Sweden
\textsuperscript{b}Aging Research Center, Karolinska Institutet, Stockholm, Sweden
\textsuperscript{c}Institute of Gerontology and Geriatrics, Department of Clinical and Experimental Medicine, University of Perugia, Italy

Accepted 5 April 2010

Abstract. The number of people suffering from Alzheimer’s disease (AD) is constantly increasing worldwide since humans live longer and age is the strongest risk factor for AD. Currently available medications for AD do not interfere with the progressive loss of synapses and neurons in the AD brain. Therefore, the development of disease modifying therapies is a major future goal. Mitochondria provide cellular energy and are crucial for proper neuronal activity and survival. Mitochondrial dysfunction is evident in early stages of AD and is involved in AD pathogenesis. The development of drugs that protect mitochondria from damage is therefore a promising strategy for AD therapy. In this review, we will discuss current available medications for AD, drugs under clinical testing, and mitochondria as a novel drug target.

Keywords: Alzheimer’s disease, drug target, mitochondria, therapy

INTRODUCTION

At present there are no disease modifying drugs for Alzheimer’s disease (AD) on the market. Available drugs include acetylcholinesterase inhibitors and memantine, both of which target neurotransmission. The overwhelming current drug development targets the production or aggregation of amyloid-\(\beta\) peptide (A\(\beta\)). However, maybe it is time to move from the idea of “one protein-one target-one drug” strategies to the development of drugs that affects organelles and have multiple targets as recently discussed by Bolognesi and colleagues [1]. Considering that AD is a complex disorder, most likely caused by several different events, it is possible that drugs with a rich pharmacology and multiple targets will be most successful in clinical trials. This does not exclude targeting A\(\beta\) production or A\(\beta\) aggregation, which certainly has an important role in AD pathogenesis, but blocking only these processes obviously may not be sufficient to improve the disease, e.g., cognitive functions in AD patients.

In this review, we will discuss currently available medications for AD and drugs under clinical testing for AD and then focus on mitochondria as a drug target in AD. Functional mitochondria are crucial both for cell survival and death as they produce cellular energy in the form of ATP and are central in apoptotic signaling. Many lines of evidence suggest that mitochondria have an important role in neurodegenerative disorders and mitochondrial dysfunction has been shown in AD, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis [2]. Therefore the mitochon-
drion has been suggested as a potential drug target in neurodegenerative disorders and drugs that affect various mitochondrial functions are under development.

CURRENTLY AVAILABLE MEDICATIONS FOR AD: TARGETING NEUROTRANSMISSION

AD is characterized by the progressive loss of basal forebrain cholinergic neurons, leading to reduction in transmission through cholinergic fibers involved in processes of attention, learning, and memory. Currently available medications for AD, acetylcholinesterase inhibitors (AChEIs) and memantine, aim to restore physiological levels of cholinergic and glutamatergic transmission, both impaired in AD brain. These drugs show efficacy during a certain period, however, the degeneration of neurons and loss of cognitive functions is unaffected and the state of patients worsen. AChEIs inhibit the enzymatic degradation of acetylcholine (ACh) and improve ACh deficit in AD. Donepezil, rivastigmine, and galantamine are AChEIs currently used for the treatment of mild and moderate AD. Donepezil also proved effective in severe AD [3] and is approved for all AD stages in several countries. Galantamine additionally modulates nicotinic receptors, while rivastigmine inhibits both AChE and butyrylcholinesterase. These mechanisms may also contribute to therapeutic efficacy. AChEIs seem equally effective in ameliorating symptoms of AD patients [4], while it is debatable whether AChEIs have disease-modifying effects. AChEIs can affect Aβ production and reduce Aβ-induced toxicity [5]. AChEIs can also modulate expression of AChE isoforms and increase expression of nicotinic receptors, events associated with cognitive improvement in AD patients [5].

Excessive glutamate levels are toxic to neurons and are considered important in AD pathophysiology. Memantine is a non-competitive, voltage-dependent antagonist of NMDA glutamate receptors, blocking excessive glutamate levels (glutamatergic excitotoxicity) without interfering with normal glutamatergic transmission [6]. As monotherapy, memantine has shown positive effects on cognition, functional status, behavior, and global function in moderate-to-severe AD [7, 8]. The drug also proved to be effective in combination with AChEIs [9,10]. As for AChEIs, a clear disease-modifying effect for memantine is not evident, but the drug shows several potential neuroprotective properties including: i) prevention of Aβ-induced neurotoxicity [6]; ii) modulation of protein-phosphatase-2A, which regulates tau phosphorylation, with consequent inhibition of neurofibrillary degeneration [11]; and iii) reduction of microglia-associated inflammation and stimulation of neurotrophic factor release from astroglia [12].

DRUGS UNDER CLINICAL TESTING FOR AD THERAPY: TARGETING PROTEINS

Abnormal misfolding and aggregation of Aβ and tau proteins leads to the two pathological hallmarks of AD: amyloid plaques and neurofibrillary tangles, respectively [13]. Aβ is generated by the sequential cleavage of amyloid-β protein precursor (AβPP) by β- (BACE1) and γ-secretases [14]. Currently, development of disease-modifying therapy in AD is largely based on anti-amyloid strategies, with compounds targeting Aβ production (e.g., BACE1 inhibitors, γ-secretase inhibitors and modulators, and α-secretase activators), aggregation and removal (e.g., active and passive immunotherapy).

Examples of drugs in clinical testing affecting BACE1 are the oral hypoglycemic drugs rosiglitazone and pioglitazone which stimulate the nuclear peroxisome proliferator-activated receptor gamma (PPARγ). These drugs reduce BACE1 and AβPP expression and thus, indirectly, the production of Aβ [15]. Other AD-related effects of PPARγ agonists are discussed under the paragraph “Impaired glucose uptake and insulin resistance” in this review. Among γ-secretase inhibitors (GSIs), semagacestat (LY450139) decreases plasma and central nervous system (CNS) Aβ levels [16,17] and is currently tested in Phase III randomized control trials (RCTs) [18]. Notch is another substrate for the γ-secretase complex and interference with Notch receptor signaling is responsible for the adverse effects of GSIs. However, Notch-sparing GSIs such as Begacestat (GSI-953), BMS-708163, NIC5-15, and PF3084014 have been developed and are being tested in humans [18].

Anti-aggregants are a chemically heterogeneous group of compounds able to bind Aβ monomers or oligomers. PBT2 is a “metal-protein attenuating compound” which binds to Aβ-Cu (or Zn) complexes. PBT2 prevents Aβ oligomerization, decreases soluble and insoluble brain Aβ, and has positive effects on cognition in animal models [19]. Potentially beneficial therapeutic properties of PBT2 include its ability to increase neuronal accessibility for metal ions and to normalize Zn and Cu concentrations in the gluta-
matergic synapse, restoring NMDA-receptor function-
ing and long term potentiation [19]. Another antiag-
gregant, now in Phase III RCT, is epigallocatechin-3-
gallate (EGCg). EGCg is a catechin from green tea
able to promote the generation of the soluble A
aggregant, now in Phase III RCT, is epigallocatechin-3-
ing and long term potentiation [19]. Another antiag-
matergic synapse, restoring NMDA-receptor function-
ing and long term potentiation [19]. Another antiag-
gregant, now in Phase III RCT, is epigallocatechin-3-
gallate (EGCg). EGCg is a catechin from green tea
able to promote the generation of the soluble A
aggregant, now in Phase III RCT, is epigallocatechin-3-
ing and long term potentiation [19]. Another antiag-
matergic synapse, restoring NMDA-receptor function-
ing and long term potentiation [19]. Another antiag-
gregant, now in Phase III RCT, is epigallocatechin-3-
gallate (EGCg). EGCg is a catechin from green tea
able to promote the generation of the soluble A
aggregant, now in Phase III RCT, is epigallocatechin-3-
ing and long term potentiation [19]. Another antiag-
matergic synapse, restoring NMDA-receptor function-
ing and long term potentiation [19]. Another antiag-
gregant, now in Phase III RCT, is epigallocatechin-3-
gallate (EGCg). EGCg is a catechin from green tea
able to promote the generation of the soluble A
aggregant, now in Phase III RCT, is epigallocatechin-3-
ing and long term potentiation [19]. Another antiag-
matergic synapse, restoring NMDA-receptor function-
ing and long term potentiation [19]. Another antiag-
gregant, now in Phase III RCT, is epigallocatechin-3-
gallate (EGCg). EGCg is a catechin from green tea
able to promote the generation of the soluble A
aggregant, now in Phase III RCT, is epigallocatechin-3-
ing and long term potentiation [19]. Another antiag-
matergic synapse, restoring NMDA-receptor function-
ing and long term potentiation [19]. Another antiag-
gregant, now in Phase III RCT, is epigallocatechin-3-
gallate (EGCg). EGCg is a catechin from green tea
able to promote the generation of the soluble A
aggregant, now in Phase III RCT, is epigallocatechin-3-
ing and long term potentiation [19]. Another antiag-
matergic synapse, restoring NMDA-receptor function-
ing and long term potentiation [19]. Another antiag-
gregant, now in Phase III RCT, is epigallocatechin-3-
gallate (EGCg). EGCg is a catechin from green tea
able to promote the generation of the soluble A
aggregant, now in Phase III RCT, is epigallocatechin-3-
ing and long term potentiation [19]. Another antiag-
matergic synapse, restoring NMDA-receptor function-
ing and long term potentiation [19]. Another antiag-
gregant, now in Phase III RCT, is epigallocatechin-3-
gallate (EGCg). EGCg is a catechin from green tea
able to promote the generation of the soluble A
aggregant, now in Phase III RCT, is epigallocatechin-3-
ing and long term potentiation [19]. Another antiag-
matergic synapse, restoring NMDA-receptor function-
ing and long term potentiation [19]. Another antiag-
gregant, now in Phase III RCT, is epigallocatechin-3-
gallate (EGCg). EGCg is a catechin from green tea
able to promote the generation of the soluble A
aggregant, now in Phase III RCT, is epigallocatechin-3-
ing and long term potentiation [19]. Another antiag-
matergic synapse, restoring NMDA-receptor function-
ings, mitochondria function [20].

Passive and active immunizations are therapeutic ap-
proaches to promote the clearance of soluble and ag-
ggregated A\(\beta\) in the CNS. The development of vac-
cines has been halted by serious adverse events that
occurred with the first vaccine (AN-1972) [21]. The
side effects of AN-1972 were related to cytotoxic
and/or autoimmune reactions. New vaccines against
A\(\beta\) (CAD106, ACC-001, V950, ACI-24, AFFITOPE
AD01 and AD02) in Phase I/II RCTs mainly target the
B-cell epitope, without stimulating T-cells. Passive im-
munotherapy includes humanized monoclonal antibod-
ies (i.e., Bapineuzumab, Solanezumab) and polyclonal
immunoglobulins (IVIg) which are now on Phase III
RCTs, may provide the opportunity to select a more ho-
mogeneous group of subjects and to measure disease-
modifying effects of a drug.

**AD AND MITOCHONDRIA**

In addition to the current strategies of AD drug de-
velopment discussed above, we need to consider other
alternatives in order to find treatments that either pre-
vent or halt the degeneration of neurons in AD brain.
Here we focus on mitochondria as targets for AD ther-
apy and discuss some examples of drugs in develop-
having direct or indirect effects on mitochondrial
function.

Neurons are dependent on aerobic oxidative phos-
phorylation for their energy needs and mitochondria are
therefore essential for neuronal function. Mitochondria
are abundant in presynaptic nerve terminals where they
provide energy for sustained neurotransmitter release.
Mitochondrial damage may lead to the release of death
factors (e.g., cytochrome c, Omi/HtrA2, Smac/Diablo)
resulting in apoptosis, which can be triggered local-
ly in synapses [30]. Dysfunctional mitochondria also
lead to decreased ATP production and impaired cal-
cium buffering capacity. No correlation has been es-
abled between the number of plaques and the cog-
nitive performance in AD patients. Instead, synaptic failure and the intracellular production of Aβ appear to correlate well with early cognitive dysfunction in AD patients [31]. It is therefore tempting to speculate that synaptic failure may be caused, at least partially, by loss of mitochondrial function induced by Aβ, for example. Indeed, it is well established that mitochondrial dysfunction is associated with neurodegenerative disorders including AD. In the early stages of AD, there is a decrease in the number of mitochondria in vulnerable neurons [32], brain glucose metabolism is decreased [33], and the activities of both tricarboxylic acid cycle enzymes [34] and cytochrome c oxidase are reduced [35–38]. Recently it was also shown that the levels of mitochondrial fission/fusion proteins are altered and that mitochondria are redistributed away from axons in pyramidal neurons of AD brain [39]. Because of the central role of mitochondria for neuronal survival, the development of therapeutic strategies to protect mitochondria and preserve mitochondrial functions in AD is important.

**Impaired glucose uptake and insulin resistance**

Neurons are unable to store glucose and are therefore dependent on the transport of glucose from the periphery across the blood-brain-barrier (BBB). This transport is insulin-dependent and glucose uptake by neurons is mediated by glucose transporters GLUT1 and GLUT3. As mentioned above, there is a reduction of glucose metabolism in the cerebral cortex, detected by 18F-2-deoxy-2-fluoro-D-glucose (FDG) positron emission tomography (PET), in early stage AD [40–42]. The reduced utilization of glucose either suggests that cerebral blood flow is reduced [43], insulin-signaling is deficient [44,45], glucose transport mechanisms are impaired [46–49], or that enzymes breaking down glucose are dysfunctional [50,51]. Interestingly, there is a well established link between AD and type II diabetes mellitus [15]. Individuals with type II diabetes and borderline diabetes have an increased risk of developing AD [52,53]. Insulin can pass the BBB and insulin receptors are expressed in brain areas important for memory formation, e.g., hippocampus and medial temporal cortex. The expression of these insulin receptors is decreased in AD, an indication of insulin resistance. It appears that functional insulin signaling is important both for memory formation and for the transport of glucose into the brain across BBB. PPARγ agonists (e.g., rosiglitazone and pioglitazone) could be beneficial in AD because of their influence on insulin levels and action, lipid metabolism, and inflammation [15], but results from large Phase III RCTs have either not been published or reported as negative [54]. Moreover, the FDA recently warned about possible cardiac risks associated with the use of rosiglitazone [55]. Small clinical tests with administration of intranasal insulin administration are ongoing [56]. Insulin-like peptides reaches the brain via extracellular pathways within 15 min after administration. Patients with early AD or MCI receiving intranasal insulin showed improved working memory, attention and functional status in a 3-week, randomized, double-blind, placebo-controlled pilot study [57]. The SNIFF-120 study is a Phase II RCT testing effects of nasal insulin on cognition, cerebral glucose metabolism, cerebrospinal fluid and plasma levels of Aβ in subjects with MCI or AD [18].

**Oxidative stress**

The brain, although representing only ~2% of the body mass, is responsible for ~20% of the total O2 consumption [58]. This is because neurons has a limited glycolytic capacity and are highly dependent on oxidative phosphorylation for ATP production, a process requiring O2. In this process, electrons are transported through protein complexes of the respiratory chain located in the mitochondrial inner membrane. During electron transport, protons are pumped out from the matrix into the inter membrane space resulting in a negative membrane potential (ψmit) across the inner membrane. At the end of the respiratory chain, O2 is reduced to H2O and ATP formed using the energy built up in the ψmit [59]. During electron transport there is a leakage of electrons from the enzyme complexes and reactive oxygen species (ROS) are produced when electrons react with O2. Reactive nitrogen species (RNS) are other free radicals normally produced in the body. ROS and RNS cause oxidative and nitrosative damage to proteins, RNA and DNA as well as peroxidation of lipids, in particular phospholipids in biological membranes [60,61]. Enzymatic (glutathione peroxidase, Mn- and CuZn-superoxide dismutases) and non-enzymatic (vitamin E, vitamin C, uric acid) antioxidants, as well as repair systems are physiologically present to counteract free radical damage. However, if the generation of ROS/RNS exceeds degradation, the redox homeostasis is altered resulting in oxidative stress and nitrosative stress. Increased protein-, RNA-, DNA- and lipid oxidative/nitrosative damage have all been detected in AD tissue, suggesting increased oxidative and nitrosative stress in AD [61,62]. These
data from human samples are supported by results from transgenic mouse models overexpressing mutated AβPP. However, clinical studies where patients receive vitamin E have not shown conclusive evidence that antioxidants have a positive effect on AD patients as discussed below. Still, aging is the major risk factor for AD and it is widely accepted that an elevation in oxidative damage is one of the most ubiquitous alterations observed in aging cells and tissues. Therefore, it is likely that increased oxidative damage contributes to the development of age-related disorders, including AD.

Aβ

Several lines of evidence point towards a role for Aβ toxicity in the mitochondrial dysfunction found in AD. We and others have shown that Aβ accumulates in mitochondria in postmortem AD brain, living patients with cortical plaques, and TgAβPP mice [63–66]. In TgAβPP mice, mitochondrial Aβ accumulation occurs prior to plaque formation, indicating that this is an early event in disease pathogenesis [63]. In vitro studies with isolated mitochondria suggest that Aβ1–42 inhibits cytochrome c oxidase activity in a copper-dependent manner [67]. Furthermore, mitochondrial Aβ-binding alcohol dehydrogenase (ABAD) has been found to be upregulated in neurons from AD patients [64] and Aβ has been shown to interact with ABAD resulting in free radical production and neuronal apoptosis. ABAD was identified as an Aβ-binding protein in a yeast two-hybrid screen [64], is localized to the mitochondrial matrix, and has an essential physiological role in mitochondria. ABAD-Aβ complexes were detected in AD brain and in Tg mutantAβPP/ABAD (Tg mAβPP/ABAD) mice. Cortical neurons cultured from Tg mAβPP/ABAD mice show increased production of ROS and decreased mitochondrial membrane potential, ATP levels and activity of respiratory chain complex IV. Consistently, these neurons displayed DNA-fragmentation and caspase-3 activity resulting in cell death by day 5–6 in culture [68]. ABAD uses NAD+ and/or NADH as its cofactor and catalyzes the reversible oxidation and/or reduction of alcohol group in its substrates [69]. The crystal structure of ABAD-Aβ complexes has been determined and shows that the NAD+ binding pocket is distorted, hindering NAD+ from binding to ABAD in the presence of Aβ [64,69]. Thus Aβ blocks ABAD activity causing mitochondrial dysfunction and ultimately cell death. Two stretches of ABAD residues in the L_D loop region (amino acids 95–113) have been shown to be important for Aβ binding. Cell permeable peptides (amino acids 92–120, ABAD-DP) protected cells from cytochrome c release, DNA fragmentation, and attenuated cell death in neuronal cultures. ABAD-DP also blocked the production of ROS both in cultured neurons and in mouse brain tissue. Small-molecule inhibitors of the ABAD-Aβ interaction belonging to a class of benzothiazole ureas have been identified [70] and ABAD emerges as a new drug target for AD.

Aβ has also been shown to specifically interact with cyclophilin D (CypD), a mitochondrial matrix protein that associates with the inner membrane during opening of the mitochondrial permeability transition pore (mPTP) [71]. Cortical mitochondria from CypD deficient mice are resistant to Aβ- and calcium-induced mitochondrial swelling and permeability transition. Moreover, Tg mAβ/CypD-null mice had improved learning and memory and synaptic function both in 12 and 24 months old animals [71,72].

Recently, it was shown that Presequence Protease (PreP) is responsible for the degradation of the accumulated Aβ in mitochondria [73]. PreP was originally found and characterized in Arabidopsis thaliana [74] as a protease degrading targeting peptides that are cleaved off in mitochondria after completed protein import as well as other unstructured peptides up to 65 amino acid residues in length, but not small proteins [75,76]. Recombinant hPreP completely degrades both Aβ40 and Aβ42 as well as Aβ Arctic protein (42,E22G) at unique cleavage sites including several sites in a very hydrophobic C-terminal Aβ29–42 segment that is prone to aggregation. Interestingly, PreP is an organellar functional analogue of the human insulin degrading enzyme (IDE), implicated in AD as it cleaves Aβ before insoluble amyloid fibers are formed [77–79].

The presence of Aβ in mitochondria indicates that it is either produced inside mitochondria and/or taken up from the outside. Both AβPP [80] and γ-secretase complexes have been detected in mitochondria and thus it is possible that Aβ is produced locally in mitochondria. However, this remains to be proven. AβPP has been shown to accumulate in AD brain mitochondria via arrested import leaving a large C-terminal part outside [80]. Under these circumstances AβPP is stuck in the mitochondrial protein import pore, consisting of the translocases of the outer- (TOM) and inner membrane (TIM), causing impairment of mitochondrial function and eventually cell toxicity. The import of AβPP is blocked due to an acidic domain at amino acids 220–290 leaving the Aβ-region outside the import pore. Re-
cent data from our laboratory show that the C-terminal part of AβPP can be inserted into the outer mitochondrial membrane (OMM) and that the mitochondrial γ-secretase cleaves AβPP to generate AβPP intracellular domain (AICD) which was detected in the inter membrane space (Pavlov et al., unpublished data). Thus it is possible that Aβ is also produced in the mitochondria and then either released on the outside or inside of the OMM. Aβ coming from the outside of mitochondria (either produced by mitochondria or transported to mitochondria via vesicles [82] or mitochondria-associated membranes [83]) can then be taken up by mitochondria and cause toxicity. Therefore we also investigated the mechanisms of Aβ uptake using isolated mitochondria treated with Aβ in the absence or presence of antibodies or inhibitors directed to various mitochondrial translocases and pores [66]. The uptake of Aβ was not affected by the presence of antibodies directed towards the voltage-dependent anion channel (VDAC) nor in the presence of Cyclosporine A which is an inhibitor of the mPTP. Interestingly, import of both Aβ1−40 and Aβ1−42 was prevented when import competent mitochondria were pre-incubated with antibodies directed toward proteins of the TOM complex, i.e., Tom20, Tom40, and Tom70. Aβ import was not affected by the addition of valinomycin, an ionophore which cause depolarization of the mitochondrial inner membrane, indicating that the Aβ import was not dependent on the ψmit. After import, Aβ was mostly localized to mitochondrial cristae and associated with the inner membrane fraction. It was earlier reported that Aβ co-localizes with the mitochondrial matrix protein Hsp60 in mouse and human samples [63]. One explanation to this discrepancy might be that in our in vitro assay, we studied Aβ localization after 30 min of import, whereas Caspersen and colleagues report data from postmortem AD brains and 8-months-old transgenic AβPP mice. However, our data from brain biopsies obtained from living subjects, displaying Aβ aggregates in the neuropil, show Aβ immuno-gold labeling in association with mitochondrial inner membranes [66]. This said, we cannot exclude the possibility that Aβ can be released or escapes from the membrane and also localizes to the matrix. In summary, these data show that Aβ is imported via the TOM complex where Tom 20 and Tom70 are receptors and Tom40 forms a pore in the OMM.

Very recently, Roses and colleagues reported data from postmortem brain deposits and early and severe cognitive dysfunction in AD patients. This would result in a modified protein that could influence the mPTP. Interestingly, import of both AβPP and AβPPsw was prevented when import competent mitochondria were pre-incubated with antibodies directed toward proteins of the TOM complex, i.e., Tom20, Tom40, and Tom70. AβPP import was not affected by the addition of valinomycin, an ionophore which cause depolarization of the mitochondrial inner membrane, indicating that the AβPP import was not dependent on the ψmit. After import, AβPP was mostly localized to mitochondrial cristae and associated with the inner membrane fraction. It was earlier reported that AβPP co-localizes with the mitochondrial matrix protein Hsp60 in mouse and human samples [63]. One explanation to this discrepancy might be that in our in vitro assay, we studied AβPP localization after 30 min of import, whereas Caspersen and colleagues report data from postmortem AD brains and 8-months-old transgenic AβPP mice. However, our data from brain biopsies obtained from living subjects, displaying AβPP aggregates in the neuropil, show AβPP immuno-gold labeling in association with mitochondrial inner membranes [66]. This said, we cannot exclude the possibility that AβPP can be released or escapes from the membrane and also localizes to the matrix. In summary, these data show that AβPP is imported via the TOM complex where Tom 20 and Tom70 are receptors and Tom40 forms a pore in the OMM.

Very recently, Roses and colleagues reported that a polymorphic poly-T variant in the TOMM40 gene can be used to estimate the age of sporadic AD onset for APOEε3 carriers. APOEε3/4 carriers with long poly-T repeats linked to APOEε3 had an age of onset 7 years earlier as compared to individuals with shorter repeats [84]. TOMM40 and APOE genes are separated by only ~2kb on chromosome 19. The effect of different poly-T lengths on the Tom40 protein are presently unknown but it is possible that it results in exon skipping as is the case for the CFTR gene with a role in cystic fibrosis. This would result in a modified protein with potentially altered function which could for example influence protein import into mitochondria. The poly-T stretch could also influence APOE transcription. The interaction between ApoE fragments and mitochondria [85] might also be influenced by the TOMM40 polymorphism. These possibilities require further investigation and would certainly link mitochondria even tighter to AD pathogenesis.

**POTENTIAL AD DRUGS AFFECTING MITOCHONDRIAL FUNCTION**

**Antioxidants**

Oxidative stress and nitrosative stress are considered important mediators in AD onset and progression [86, 87]. Increased levels of different biomarkers of oxidative and nitrosative stress damage have been found in diseased brain regions and peripheral tissues of patients with AD, and similar findings were reported in subjects with mild cognitive impairment (MCI) [61]. Since individuals with MCI are at increased risk of developing dementia [88], the evidence of oxidative stress and nitrosative stress in subjects with MCI suggests that these are early events in cognitive decline.

Some studies report reduced concentrations of plasma antioxidant micronutrients in subjects with AD and MCI [89,90], suggesting an inadequate antioxidant activity in these disorders, and antioxidants have received great attention as a possible means to prevent and treat AD. Within this category, vitamin E is the major lipid-soluble, chain-breaking, non-enzymatic antioxidant in the body, with a key role in protecting cellular membranes. This could be crucial in mitochondria, which are both high-energy source and elective target of free radicals. α-Tocopherol is the vitamin E form with the highest bioavailability in humans, and it is the most investigated in AD. Double transgenic mice model of AD (Ttpa−/− AβPPsw), knockout for the α-tocopherol transfer protein (α-TTP) and thus with systemic α-tocopherol deficiency, showed increased Aβ brain deposits and early and severe cognitive dysfunc-
tion, all events being improved by α-tocopherol supplementation [91]. Mito-E₂, generated by conjugating α-tocopherol to the lipophylic cation triphenylphosphonium (TPP⁺), is a mitochondria-targeted antioxidant that is selectively enriched in mitochondria. Mito-E₂ can efficiently distribute in peripheral tissues, including CNS in mice [92], and it has been shown to protect from oxidative damage [93] and influence Ca²⁺ signaling in cellular models [94].

The use of α-tocopherol has been evaluated in several neurological disorders associated with increased oxidative stress, such as AD, Parkinson’s disease, and amyotrophic lateral sclerosis [95]. Results from RCTs on α-tocopherol in AD and MCI therapy are conflicting [96], and methodological problems could explain, at least in part, this inconsistency. Short duration of the supplementation and too advanced disease stage have been used to explain the negative results, which could be also due to the choice of the wrong dosage and/or the use of only α-tocopherol. Indeed vitamin E is a family of eight natural compounds (four tocopherols and four tocotrienols), all acting as antioxidants [97], and each form shows unique biological functions (i.e., anti-inflammatory activity and modulation of different signaling pathways) that can contribute to neuroprotection [98]. Epidemiological studies suggest that the protective effect of vitamin E against AD can be due to the contribution of different forms [99,100], while in RCTs only α-tocopherol has been used, often in high doses. Intake of high doses of α-tocopherol can decrease the bioavailability of the other vitamin E forms [101,102] and has been associated with an increased mortality risk [103], suggesting that a balanced combination of vitamin E forms is important for neuroprotection, and that supplement composition needs to be refined. Another important issue worth consideration in supplementation studies is the importance of assessing biomarkers (i.e., antioxidants, markers of oxidative stress/nitrosative stress) before and after the intervention, in order to identify subjects who could benefit from the supplementation and to monitor compliance and response to treatment.

Coenzyme Q₁₀ (ubiquinone) is another antioxidant investigated in neurodegenerative diseases. Coenzyme Q₁₀, synthesized by the human body, is a cofactor in the mitochondrial electron transport chain and is thus essential for ATP production. In a mouse model of AD, coenzyme Q₁₀ supplementation reduced Aβ₂₅ levels in the cortex and decreased levels of markers of oxidative stress [104]. Phase III RCTs with Coenzyme Q₁₀ are ongoing in subjects with Huntington’s disease and Parkinson’s disease [18], while currently there are no studies on AD subjects.

MitoQ₁₀ is the TPP⁺ conjugated form of coenzyme Q₁₀, that is selectively accumulated in the mitochondrial matrix [94]. MitoQ₁₀ has been shown to reach peripheral tissues and to protect against oxidative damage in animal models [93]. MitoQ₁₀ affects Ca²⁺ homeostasis in cellular models but, as with Mito-E₂, this effect seems to be mediated mainly by TPP⁺ [94]. How this can influence the effect of the antioxidants on mitochondria is not yet clear. Thus, when using complex molecules it is essential to understand the interaction between mitochondria and shuttle compounds, such as TPP⁺, which allows selective accumulation of the active drug but could independently influence mitochondrial components.

Dimebon (latrepirdine)

Dimebon was originally approved in the former Soviet Union as a non-selective antihistamine for skin allergy and allergic rhinitis [105], but was withdrawn from the market with the advent of more selective treatments. Dimebon attracted renewed interest due to findings suggesting a neuroprotective effect [106–108]. In a Phase II AD trial, Dimebon treatment was associated with benefits on cognition, global function, activities of daily living, and behavior [109]. Several Phase III clinical trials are ongoing for both AD and Huntington’s disease [18]. The first reported data from the CONNECTION study, where patients received Dimebon or placebo for six months, did not meet primary or secondary efficacy endpoints. However, it should be noted that neither group was significantly changed from baseline. Dimebon exhibits a rich pharmacological profile and binds to histamine-, adrenergic-, dopamine-, and serotonin-receptors [108,110]. It is known to be a weak inhibitor of: acetylcholinesterase (IC₅₀ = 8–42 µM) [107], N-methyl-D-aspartate (NMDA) receptors (IC₅₀ = 10 µM) [108,111], and voltage-gated calcium channels (IC₅₀ = 50 µM) [108,112]. In addition, µM concentrations of Dimebon have previously been shown to protect against neuronal cell death induced by Aβ₁₋₄₂ [107] and to modulate the mPTP (10–200 µM) [113]. In a recent study from our laboratory [114] we show that nM concentrations of Dimebon (1 to 5 days incubation) results in an increase of ψmit (hyperpolarization) and cellular ATP levels both in mouse cortical neurons and human neuroblastoma cells. Moreover, Dimebon pretreatment made cells more resistant to depolarization of ψmit-induced by high intracellular
calcium concentrations. Cells were also protected from undergoing cell death induced either by calcium stress or withdrawal of growth factors. Our study suggests that Dimebon directly or indirectly affects mitochondria making cells more resistant to cell death stimuli.

In another study of the mode of action of Dimebon, the effect on intracellular protein inclusions was investigated in a cellular model of TDP-43 proteinopathy. Yamasita and colleagues showed that 1µM concentrations of Dimebon (3 days incubation) decreased the number of TDP-43 aggregates in human neuroblastoma SH-SY5Y cells expressing mutant TDP-43 [115]. This study suggests that Dimebon possess anti-oligomerization properties. Additionally, Steele and colleagues have studied the effect of Dimebon on Aβ secretion in three different model systems [116]. In mouse neuroblastoma N2a cells overexpressing hAβ40, a 6 h treatment with Dimebon (500 pM–5 µM) resulted in an increase in total extracellular Aβ. No significant changes in Aβ42/Aβ40 were observed. The release of Aβ from synaptosome-isolated from tgCRND8 mice (hAβ42/wt/ind) was studied after short time (1–10 min) incubation with Dimebon (1 or 10 µM). In this model system, the secretion of Aβ42 was elevated in Dimebon treated samples. Finally, a 41% increase in Aβ42 levels was detected in the interstitial fluid from the brains of Tg2576 mice (hAβPPsw/ind) analyzed 10 h following injection of 3.5 mg/kg Dimebon. The Dimebon stimulated Aβ secretion could be caused by changes in neurotransmission, coupled with synaptic activity, or by effects on Aβ oligomerization. A mechanistic link between the effects observed in cell- and animal models could be that Dimebon simultaneously strengthen mitochondrial functions and increases Aβ secretion from neurons and brain. This is at present highly speculative and needs further investigation.

CONCLUSIONS

Drugs available for AD include acetylcholinesterase inhibitors and memantine both targeting neurotransmission. Current developments in therapies for AD are largely based on anti-amyloid strategies and it remains to be shown that such approaches will be disease-modifying or improve cognitive functions. One alternative strategy is to target mitochondria which are central for neuronal survival and shown to have impaired function in neurodegenerative disorders. To specifically target an organelle with double membranes is a challenge since the compound has to pass through the BBB, cell membrane, and mitochondrial membrane. For the last step, one can take advantage of the fact that the matrix of mitochondria is negatively charged and that positively charged molecules will accumulate inside mitochondria, e.g., MitoQ and Mito-E2. Lipophilic cations may accumulate 100- to 1000-fold in mitochondria. This strategy has so far been tested with antioxidants but other small molecules that, for example, block Aβ-ABAD interactions or mitochondrial Aβ-uptake, could also be targeted to mitochondria using the same principle. Preservation of proper mitochondrial function is central for the maintenance of synaptic activity and neuronal function in general. Since mitochondria are affected in early stage AD, strategies to develop drugs that protect mitochondria from damage are worth pursuing.

DISCLOSURE STATEMENTS

Authors’ disclosures available online (http://www.j-alz.com/disclosures/view.php?id=399).

REFERENCES


S58


